Effects of Nicotinamide Riboside on Metabolism and Vascular Function
NCT ID: NCT03501433
Last Updated: 2020-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2018-02-01
2019-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nicotinamide Riboside and Metabolic Health
NCT02835664
Effects of Niacin Therapy on Lipoprotein Composition and Function
NCT02322203
Effects of Niacin On Fatty Acid Trapping
NCT01984073
Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis
NCT01250990
Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression
NCT00176020
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nicotinamide Riboside Chloride (Niagen)
7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).
Nicotinamide riboside chloride (Niagen)
250 mg capsules 2x/day for 7 days
Placebo
7 days of placebo supplementation (2/day)
Placebo
2x/day for 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotinamide riboside chloride (Niagen)
250 mg capsules 2x/day for 7 days
Placebo
2x/day for 7 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normo- or pre-hypertensive (blood pressure \<140/90 mmHg)
* Non-smokers
* Able to give informed consent and participate in all laboratory visits
Exclusion Criteria
* Known metabolic (e.g. Type I or Type II diabetes, cardiovascular disease, etc.) or immunologic (e.g. HIV, cancer, autoimmune, etc.) diseases
* Food allergies to egg, milk, soy or wheat
* Women who are pregnant or planning to become pregnant during the course of the study,
* Pacemaker or other implanted device
* Unwilling to participate in the experimental protocol or blood draws will be excluded
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iowa State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rudy Valentine
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rudy Valentine, PhD
Role: PRINCIPAL_INVESTIGATOR
Iowa State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Iowa State University
Ames, Iowa, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-603
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.